证券代码：601567 证券简称：三星医疗 公告编号：临 2025-088 宁波三星医疗电气股份有限公司 关于经营合同预中标的提示性公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波三星医疗电气股份有限公司（以下简称"公司"）及下属全资子公司宁波奥克 斯智能科技股份有限公司（以下简称"奥克斯智能科技"）于近日在国网江苏省电力有 限公司 2025 年第二次配网物资协议库存公开招标采购项目、国网安徽电力 2025 年第 二次物资协议库存公开招标采购项目中被推荐为中标候选人，预计合计中标总金额约 为 12,529.07 万元，现将预中标情况公告如下： 一、国家电网项目预中标的主要内容 1、国网江苏省电力有限公司2025年第二次配网物资协议库存公开招标采购项目 国家电网有限公司于近日在其电子商务平台（http://ecp.sgcc.com.cn）公告"国网 江苏省电力有限公司2025年第二次配网物资协议库存公开招标采购推荐的中标候选 人公示"（招标编号：1025AB），奥克斯智能科技为中标候选人。 https://ecp.sgcc. ...

Group 1 - Samsung Medical (601567.SH) announced that it and its wholly-owned subsidiary, Ningbo Aux Intelligent Technology Co., Ltd. (referred to as "Aux Intelligent Technology"), have been recommended as candidates for winning bids in two public procurement projects by State Grid Jiangsu Electric Power Co., Ltd. and State Grid Anhui Electric Power Co., Ltd. for the year 2025 [1] - The total expected bid amount for these projects is approximately 125 million yuan [1]

Core Insights - Samsung Medical (601567.SH) announced that it and its wholly-owned subsidiary, Ningbo Aux Intelligent Technology Co., Ltd., have been recommended as candidates for winning bids in two public procurement projects by State Grid Jiangsu Electric Power Co., Ltd. and State Grid Anhui Electric Power Co., Ltd. for 2025 [1] Group 1 - The total expected bid amount for the projects is approximately 125 million yuan [1]

Core Viewpoint - Samsung Medical (601567.SH) and its wholly-owned subsidiary, Ningbo Aux Intelligent Technology Co., Ltd., have been recommended as candidates for winning bids in two public procurement projects by State Grid Jiangsu Electric Power Co., Ltd. and State Grid Anhui Electric Power Co., Ltd., with a total expected bid amount of approximately 125 million yuan [1] Group 1 - The company has participated in the 2025 second round of public procurement projects for inventory materials [1] - The total expected bid amount from both projects is around 125 million yuan [1]

Core Viewpoint - Samsung Medical announced that it and its wholly-owned subsidiary, Aix Smart Technology, have been recommended as candidates for winning bids in two public procurement projects by State Grid Jiangsu Electric Power Company and State Grid Anhui Electric Power Company, with a total expected bid amount of approximately 125.29 million yuan [1] Group 1 - The total expected bid amount for the projects is approximately 125.29 million yuan [1] - The project with State Grid Jiangsu Electric Power Company is expected to win a bid of 64.71 million yuan [1] - The project with State Grid Anhui Electric Power Company is expected to win a bid of 60.58 million yuan [1] Group 2 - Winning these bids is anticipated to have a positive impact on the company's performance [1] - The company has not yet received the official bid notification, indicating uncertainty regarding the performance impact [1]

Core Viewpoint - Samsung Medical (601567) announced that it and its wholly-owned subsidiary, Ningbo Aokeshi Intelligent Technology Co., Ltd., have been recommended as candidates for winning bids in two public procurement projects for inventory materials by State Grid Jiangsu Electric Power Co., Ltd. and State Grid Anhui Electric Power Co., Ltd., with a total expected bid amount of approximately 125 million yuan [1]. Group 1 - Company and its subsidiary have been recommended as winning candidates in public procurement projects [1] - Total expected bid amount is approximately 125 million yuan [1]

Group 1 - On November 17, Samsung Medical experienced a decline of 2.46% with a trading volume of 472 million yuan, and the net financing buy was -41.71 million yuan [1] - As of November 17, the total financing and securities lending balance for Samsung Medical was 308 million yuan, with a financing balance of 304 million yuan, accounting for 0.84% of the circulating market value [1] - The company’s main business revenue composition includes 79.70% from the power sector, 19.15% from medical services, and 1.15% from other businesses [1] Group 2 - As of September 30, the number of shareholders for Samsung Medical increased by 15.72% to 33,500, while the average circulating shares per person decreased by 13.94% to 41,941 shares [2] - For the period from January to September 2025, Samsung Medical reported a revenue of 11.08 billion yuan, representing a year-on-year growth of 6.19%, while the net profit attributable to the parent company was 1.528 billion yuan, a decrease of 15.85% year-on-year [2] Group 3 - Since its A-share listing, Samsung Medical has distributed a total of 6.407 billion yuan in dividends, with 3.329 billion yuan distributed in the last three years [3] - As of September 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder of Samsung Medical, holding 51.056 million shares, an increase of 3.0756 million shares compared to the previous period [3]

Core Viewpoint - Samsung Medical has been recognized as a candidate for a major procurement project by the State Grid Corporation of China, with an expected total bid amount of approximately 168 million yuan, which will strengthen its position in the domestic power grid market and drive annual performance growth [1][2]. Group 1: Recent Achievements - Samsung Medical's subsidiary, Aixs Intelligent Technology, has been recommended as a candidate for a procurement project that includes key electrical equipment such as overhead insulated wires and 10KV transformers [1][2]. - Since 2025, Samsung Medical has secured significant orders, with a total order backlog of 17.914 billion yuan as of the end of the third quarter of 2025, representing a year-on-year increase of 14.69% [1][2]. Group 2: Financial Performance - The company reported revenues of 9.098 billion yuan, 11.46 billion yuan, and 14.6 billion yuan for the years 2022 to 2024, with year-on-year growth rates of 29.55%, 25.99%, and 27.38% respectively [4][5]. - In the first three quarters of 2025, the company achieved revenue of 11.08 billion yuan, a year-on-year increase of 6.19%, but the net profit attributable to shareholders decreased by 15.85% to 1.528 billion yuan [5]. Group 3: Research and Development - Samsung Medical has invested heavily in R&D, with total R&D expenses exceeding 2.037 billion yuan over the past five years, which has strengthened its technological capabilities and product competitiveness [4][6]. - The company has received 32 automation patents in the last three years and is advancing its "smart manufacturing" strategy, including the establishment of the industry's first digital factory [6].

Core Points - Samsung Medical (601567) reported that as of the end of the third quarter of 2025, the total number of shareholders reached 33,504 [1]

Group 1 - Yongtai Technology's wholly-owned subsidiary has received approval for trial production of a lithium battery additive project with an annual capacity of 5,000 tons, set to begin trial production [1] - Mengke Pharmaceutical has decided to terminate its plan to issue shares to a specific entity due to ongoing disagreements among major shareholders, which could impact the company's stable operations [1] - Anhui Construction's subsidiary has been approved to register and issue debt financing tools totaling 15 billion yuan, including 5 billion yuan in short-term financing notes and 10 billion yuan in medium-term notes [2] Group 2 - Koli'er plans to repurchase shares worth between 10 million and 20 million yuan, with a maximum repurchase price of 20.94 yuan per share, to implement an employee stock ownership plan [2] - Xinhua Pharmaceutical has received approval for the production of fumaric acid volnoral raw materials, which are used to treat gastroesophageal reflux disease [3] - Lianhuan Pharmaceutical has received approval for additional specifications of tadalafil tablets, expanding its product offerings for treating erectile dysfunction and benign prostatic hyperplasia [5] Group 3 - Greenland Holdings reported an increase of 1,834 lawsuits with a total amount of 6.587 billion yuan from October 21 to November 13, 2025 [7] - Lianke Technology plans to invest up to 600 million yuan of idle funds in low-risk financial products [8] - Yinglian Co. signed a strategic procurement contract for 5,000 million square meters of composite aluminum foil with a leading new energy technology company [10] Group 4 - China Eastern Airlines reported a 10.58% year-on-year increase in passenger turnover for October, with a capacity increase of 6.84% [12] - China National Airlines reported an 8.7% year-on-year increase in passenger turnover for October, with domestic and international capacity also showing growth [15] - Oupai Home plans to use 320 million yuan of idle funds to purchase structured deposits with expected annual yields between 0.65% and 2.50% [16] Group 5 - Tianwei Food has submitted H-share issuance application materials to the Hong Kong Stock Exchange, which have been accepted by the China Securities Regulatory Commission [18] - Guizhou Aviation plans to establish a subsidiary focused on the research, production, and market expansion of intelligent automotive components, with initial operating funds of 40 million yuan [20] - Daimai Co. plans to invest 100 million yuan to establish a wholly-owned subsidiary in Shanghai focused on robotics technology [22] Group 6 - Founder Securities has received approval to issue company bonds totaling up to 30 billion yuan [24] - Hengrui Medicine has received clinical trial approvals for multiple drugs, indicating ongoing research and development efforts [26] - Zhaojing Pharmaceutical's product ZG006 has received orphan drug designation from the FDA, providing various benefits for its development in the U.S. market [39]